drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous CD19-directed CAR T-cell therapy that redirects T cells to CD19+ B cells to induce cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lisocabtagene Maraleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD19-directed chimeric antigen receptor T-cell therapy. Patient T cells are engineered to express a CAR (with 4-1BB costimulatory and CD3ΞΆ signaling domains) that binds CD19 on B cells, triggering T-cell activation, proliferation, and cytotoxic killing of CD19+ malignant B cells.
drug_name
Lisocabtagene maraleucel (liso-cel)
nct_id_drug_ref
NCT06205290